New AI tool to spot skin cancer to be used in NHS
It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend.
Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer.
AI is being deployed to speed up the diagnosis of skin cancer and free up capacity within dermatology.
DERM assesses and classifies scans of moles or skin lesions that have been taken by a healthcare professional, after patient is referred by a GP for suspected skin cancer. pic.twitter.com/unqGj0Myv7
— Bolton NHS Foundation Trust (@boltonnhsft) April 2, 2025
The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous.
The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions.
The images are then uploaded on to DERM's online platform, which uses AI to analyse the images.
For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient.
People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'.
Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'.
It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said.
'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice.
'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.'
Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.'
Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.'
The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist.
'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.'
The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed.
It comes as Melanoma Focus warned about the dangers of sunburn among Britons.
'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus.
A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups.
Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences.
'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.'
The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all.
Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
4 hours ago
- The Independent
Why the NHS may never use breakthrough Alzheimer's drugs
The National Institute for Health and Care Excellence (Nice) is expected to refuse the use of Alzheimer's drugs lecanemab and donanemab on the NHS, despite their success in slowing the disease's progression. The regulator's decision will reportedly be based on cost-effectiveness, as the drugs are estimated to cost between £20,000 to £25,000, which is considered too high for the limited benefit they provide. Trials showed lecanemab can slow Alzheimer's progression by 27 per cent over 18 months by removing build-ups of the protein beta-amyloid from the brain, while donanemab teaches the body's immune cells to remove the amyloid protein. Around 70,000 adults would have been eligible for treatment if the drugs had been approved. Both drugs have UK drug licenses and are available privately, but Nice estimates that the cognitive decline slowed by donanemab is not enough to justify the cost to the NHS. Alzheimer's Research UK expressed disappointment, stating that while the treatments are not perfect, they represent a vital foundation for further scientific progress.
The Independent
15 hours ago
- The Independent
Thousands of NHS patients ‘to be denied breakthrough Alzheimer's drugs'
Breakthrough drugs that slow the progression of Alzheimer's disease will reportedly be refused for use on the NHS this week in a blow to thousands of patients. The two drugs, Lecanemab and donanemab, slow down the decline in Alzheimer's patients' ability to carry out daily activities. The drugs' success in halting the progression of Alzheimer's was heralded as a 'new era' by campaigners and researchers. However, the National Institute for Health and Care Excellence (Nice) is expected to refuse to recommend them on the NHS, according to The Sunday Times. The regulator has already issued two decisions, one in October last year and another in March, saying they would not recommend the drugs for use on the NHS. A final decision will be published on Thursday. Both drugs already have UK drug licences, making them available privately. It is estimated that around 70,000 adults in England would have been eligible for treatment if the drugs had been approved. The regulator will reportedly turn down both drugs on the grounds of cost-effectiveness, with one insider telling The Sunday Times: 'It is the end of the road for these drugs on the NHS'. Lecanemab removes build-ups of the protein beta-amyloid from the brain. Trials showed that lecanemab can slow the progression of Alzheimer's by 27 per cent over 18 months if given to someone early on in the course of their decline. Donanemab, marketed as Kisunla in the UK, teaches the body's immune cells to recognise and remove the amyloid protein, which builds up in the brains of people with Alzheimer's disease. The protein build-ups are thought to be toxic to brain cells, leading to the symptoms of Alzheimer's, the Alzheimer's society has said. Lecanemab can, however, cause swelling and bleeding in the brain. In trials for Donanemab, a third of recipients experienced abnormalities in their brain scans caused by brain swelling and bleeding, NICE said. The drugs reportedly cost around £20,000 to £25,000, with the NHS being offered a lower price. Privately, the treatment costs between £60,000-80,000 per year, according to Alzheimer's Research UK. In a previous review by NICE in October 2024, director of medicines evaluation Helen Knight said: 'Donanemab could slow down cognitive decline by 4-7 months, but this is just not enough benefit to justify the additional cost to the NHS. The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources'. While the regulator said the decision would be disappointing for some, 'there are other treatments being developed'. Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said the decision to turn down the drugs would be 'deeply disappointing'. She added: 'These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.' The regulator NICE is due to publish the final draft guidance about the two drugs on Thursday. This leaves space for the decision to be challenged and sent to a review panel before the final guidance is published.
ITV News
3 days ago
- ITV News
World-first 'Trojan horse' drug to be given to blood cancer patients in England
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. Studies suggest the targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or has not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future.'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation.'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
